Register now!

Who should join?

Industries and research organisations who are impacted by EU policy in these areas should consider membership of the association. 

Medical Devices Industry

The medical device industry has a great deal to gain from in silico medicine. Advances in modelling and simulation have led to development of more effective medical devices and the integration of software, devices and medicinal products require a holistic regulatory approach to their evaluation. 

Policies need to be created to ensure that modelling and simulation is used correctly so that the safest and most effective medical devices can be put on the market to the benefit of all.

Software Industry

A lack of framework for the validation of in silico models is a major barrier to those software industries engaged in healthcare. The Avicenna Alliance will work towards the creations of such a framework that would allow for maximum market uptake of medical software for pre-clinical and clinical use.

Data Protection and ensuring ease of access to health data for medical research purposes is a key priority of the Alliance.

Cosmetic Industry

The recent EU ban on animal testing for cosmetic purposes has laid down the gauntlet for cosmetic companies to find suitable alternatives to test their products. In silico methods provide the best hope for feasible alternatives to maintain the development of new products without impacting on the welfare of animals. 

Pharmaceutical Industry

An overall declining research pipeline, rise in anti-microbial resistance coupled with a huge spike in the cost of research in recent years are a cause of concern for the pharmaceutical industry. 

read more

Non-Commercial Research and Academic Institutions

Research has turned into a truly competitive environment, where heterogeneous interests heavily interfere with the strategic decisions on what should or should not be funded. The VPH Institute focuses on ensuring that in silico medicine research receives an adequate level of funding, by advising the European Commission on the creation of a policy and regulatory framework that is favourable to the adoption of in silico medicine. Your support as a member of the VPH Institute will not only be instrumental in contributing to the transformation of current biomedical research, but it may also improve the quality and the scope of your own R&D and expand your funding base.

Interested to join the VPH Institute?
Find out more information on VPHi website


Interested in
 Avicenna Alliance?

To find out more about how the Avicenna Alliance could benefit your industry, email Adriano Henney:

Contact us

Avicenna Alliance news

And the EMA goes to… Amsterdam!

During a General Affairs Council meeting on 20 November, the EU27 ministers decided on the new location of the European Medicines Agency (EMA) and the European Banking...

find out more ›

Commission adopts 2018 Work Programme

Following on from the announcements made in President Juncker's 2017 State of the Union Address, the European Commission adopted on 24 October 2017 its 2018 Work...

find out more ›

Avicenna Alliance interview for ANSYS

For the Avicenna Alliance, in silico medicine is the obvious connect between the promise of big data and the need for personalised medicine. In an interview for...

find out more ›

Show all activites